Evidence map›Paper›PMID 33742317›Full record

ReviewGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?

Giandomenico Roviello, Giuseppe Aprile, Alberto D'Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini, Martina Catalano

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  12. Article
  13. PreoperativeQuantitative imaging in medicine and surgery · 2023
    Article
  14. HomodimerMedical oncology (Northwood, London, England) · 2022
    Article
  15. Review
  16. Article
  17. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.ORCID 0000-0001-5504-8237
Giuseppe AprileDepartment of Oncology, San Bortolo General Hospital, Vicenza, Italy.
Alberto D'AngeloDepartment of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK.
Luigi Francesco IannoneDepartment of Health Science, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Franco RovielloDepartment of Medical, Surgical and Neuro Sciences, Section of Surgery, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
Karol PolomDepartment of Medical, Surgical and Neuro Sciences, Section of Surgery, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
Enrico MiniDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
Martina CatalanoSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
University of Florence · ITUniversity of Siena · ITMagna Graecia University · ITOspedale San Bortolo · ITUniversity of Bath · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is one of the most common malignancy worldwide. In unresectable or metastatic disease, the prognosis is poor and in generally less than a year. HER2 expression remains an important biomarker to lead the addition of trastuzumab to first-line systemic chemotherapy in unresectable or metastatic gastroesophageal adenocarcinoma. To date, a major issue is represented by resistance to trastuzumab developed during treatment, considering the not improved outcomes in this molecular subtype of gastroesophageal adenocarcinoma to other HER2 target strategies. In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance to HER2-targeted therapy and current challenges in the treatment of HER2-positive advanced gastric cancer refractory to trastuzumab. Furthermore, we describe the prognostic value of new non-invasive screening methods, under development novel agents (e.g., HER2 antibody-drug conjugates and bispecific antibodies) and strategies with antitumor activity in early studies.

Indexed as

Antineoplastic Agents, ImmunologicalBiomarkers, TumorDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesHumansPrognosisStomach NeoplasmsTrastuzumabAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabHER2PertuzumabTrastuzumab

Identifiers

PMID33742317
OpenAlexW3136854556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.